Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP

Objectives: This study sought to investigate plasma levels of circulating cardiac natriuretic peptides, atrial natriuretic peptide (ANP) and B-type or brain natriuretic peptide (BNP), in the general community, focusing on their relative differences in worsening human hypertension. Background: Although ANP and BNP are well-characterized regulators of blood pressure in humans, little is known at the population level about their relationship with hypertension. The authors hypothesized that hypertension is associated with a lack of activation of these hormones or their molecular precursors. Methods: The study cohort (N = 2,082, age >45 years) was derived from a random sample from Rochester, Minnesota, and each subject had a medical history, clinical examination, and assessment of different plasma forms of ANP and BNP. Patients were stratified by blood pressure. Multivariable linear regression was used to assess differences in natriuretic peptide levels in worsening hypertension. Results: Compared to normotensive, BNP_1-32 and N-terminal proBNP_1-76 (NT-proBNP_1-76) were significantly decreased in pre-hypertension (p < 0.05), with BNP_1-32 significantly decreased in stage 1 as well (p < 0.05). Although proBNP_1-108 remained unchanged, the processed form was significantly increased only in stage 2 hypertension (p < 0.05). ANP_1-28 remained unchanged, while NT-ANP_1-98 was reduced in pre-hypertension (p < 0.05). Conclusions: The authors demonstrated the existence of an impaired production and/or release of proBNP_1-108 along with a concomitant reduction of BNP_1-32 and NT-proBNP _1-76 in the early stages of hypertension, with a significant elevation only in stage 2 hypertension. Importantly, they simultaneously demonstrated a lack of compensatory ANP elevation in advanced hypertension.